HR+/HER2- Breast Cancer: Excitement for Upcoming Clinical Trial Readouts
Key opinion leaders in breast cancer management share their excitement for data that will be released at the annual ASCO meeting in 2022 or the near future.
Addressing Unmet Needs in HR+/HER2- Metastatic Breast Cancer
Before closing out their discussion on CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, experts highlight remaining unmet needs in this setting.
Overcoming Resistance in HR+/HER2- mBC: Other Novel Targeted Agents
Broad perspectives on various novel mechanisms of action that may address acquired resistance to therapies for HR+/HER2- metastatic breast cancer.
Overcoming Resistance in HR+/HER2- mBC: Novel ADC and SARM Therapy
Considerations for how novel antibody drug conjugates (ADCs) and selective androgen receptor modulators (SARMs) may respectively address mechanisms of resistance within HR+/HER2- metastatic breast cancer.
Mechanisms of Resistance to CDK4/6- and ER-Targeted Therapy in Metastatic BC
Key opinion leaders share insight on various mechanisms of resistance to frontline therapy in patients with HR+/HER2- metastatic breast cancer.
HR+/HER2- Metastatic Breast Cancer: Real-World Data on CDK4/6 Inhibitors
A brief review of molecular testing’s role in HR+/HER2- metastatic breast cancer and how certain driver mutations can impact care.
Importance of Molecular Testing in HR+/HER2- Metastatic Breast Cancer
HR+/HER2- Metastatic Breast Cancer: Selecting From Approved CDK4/6 Inhibitors
Richard Finn, MD, considers data behind all three approved CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer and how they compare.
MONARCH 2 and MONARCH 3: Pooled Analysis of Abemaciclib + Fulvestrant
Expert perspectives on the pooled analysis from MONARCH 2 and MONARCH 3, combining frontline abemaciclib with fulvestrant.
MONALEESA-2 and MONALEESA-3: Frontline Ribociclib + Endocrine Therapy
Highlights from the MONALEESA-2 and -3 trials combining frontline ribociclib with endocrine therapy in patients with HR+/HER2- metastatic breast cancer.
PALOMA-2 and PALOMA-3: Time to Chemotherapy on Palbociclib + Endocrine Therapy
Time-to-chemotherapy results of the PALOMA-2 and -3 trials in HR+/HER2- metastatic breast cancer, which combined frontline palbociclib and endocrine therapy.
Factors in Selecting Frontline Therapy for HR+/HER2- Metastatic Breast Cancer
Shared insight on how best to select frontline therapy, alone or in combination, for patients with HR+/HER2- mBC.
HR+/HER2- Metastatic Breast Cancer: Treatment Armamentarium
Expert Harold Burstein, MD, PhD, breaks down the treatment armamentarium for patients with HR+/HER2- metastatic breast cancer.
Evolving Treatment Landscape of HR+/HER2- Metastatic Breast Cancer
Massimo Cristofanilli, MD, FACS, provides a historical overview of the HR+/HER2- metastatic breast cancer (mBC) treatment landscape.
Dr. Burstein Discusses Key Updates from the SOFT Trial
Harold Burstein, MD, PhD, medical oncologist, Dana-Farber Cancer Institute discusses some key findings from the follow-up data from the SOFT trial.
Dr. Burstein on Adjuvant Endocrine Therapy for ER+ Breast Cancer
Harold J. Burstein, MD, PhD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses adjuvant endocrine therapy for postmenopausal women with ER-positive breast cancer.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512